All In MedTech

FDA Clearance Tracker · P230042

Optune Lua

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Oct 15, 2024 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Oct 15, 2024

Approved

Time to decision

305 days

Received Dec 15, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P230042
Device name
Optune Lua
Applicant location
Baar
Received
Dec 15, 2023
Decided
Oct 15, 2024
Decision
Approved
Supplements
7 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code SDA

FDA's approval statement

As written in FDA's record.

Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel is indicated for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code SDA (Electrical tumor treatment fields for non-small cell lung cancer).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Novocure, GmbH

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.